CoChat

CV Protection in the EMPA-REG OUTCOME Trial: A “Thrifty Substrate” Hypothesis

Ferrannini, Ele, Mark, Michael, Mayoux, Eric · 2016 · Diabetes Care

The DOI matches its Crossref record; 77 of the 77 references it cites were found in a registry or an index.

Abstract

The striking and unexpected relative risk reductions in cardiovascular (CV) mortality (38%), hospitalization for heart failure (35%), and death from any cause (32%) observed in the EMPA-REG OUTCOME trial using an inhibitor of sodium–glucose cotransporter 2 (SGLT2) in patients with type 2 diabetes and high CV risk have raised the possibility that mechanisms other than those observed in the trial—modest improvement in glycemic control, small decrease in body weight, and persistent reductions in blood pressure and uric acid level—may be at play. We hypothesize that under conditions of mild, persistent hyperketonemia, such as those that prevail during treatment with SGLT2 inhibitors, β-hydroxybutyrate is freely taken up by the heart (among other organs) and oxidized in preference to fatty acids. This fuel selection improves the transduction of oxygen consumption into work efficiency at the mitochondrial level. In addition, the hemoconcentration that typically follows SGLT2 inhibition enhances oxygen release to the tissues, thereby establishing a powerful synergy with the metabolic substrate shift. These mechanisms would cooperate with other SGLT2 inhibition–induced changes (chiefly, enhanced diuresis and reduced blood pressure) to achieve the degree of cardioprotection revealed in the EMPA-REG OUTCOME trial. This hypothesis opens up new lines of investigation into the pathogenesis and treatment of diabetic and nondiabetic heart disease.

Overview

Integrity signals

Registry

Crossref · 10.2337/dc16-0330

Cites

77 of 77 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Citations

Cites

Cited by

See all 1,000

Metadata

Authors
Ferrannini, E., Mark, M., & Mayoux, E.
Affiliations
  • Istituto di Fisiologia Clinica (IT)
  • Boehringer Ingelheim (Germany) (DE)
Corresponding author
Ferrannini, Ele
Venue
Diabetes Care
Published
2016-06-11
Volume
39
Issue
7
Pages
1108-1114
ISSN
  • 0149-5992 (ISSN-L)
  • 1935-5548
OpenAlex
W2412800896
Cited by
975
References
77
Citations by year
2026: 53 · 2025: 53 · 2024: 73 · 2023: 79 · 2022: 91 · 2021: 134 · 2020: 114 · 2019: 100 · 2018: 110 · 2017: 119 · 2016: 47
FWCI
125.98
Type
journal article
Language
en
Open access
closed
Locations
  • Diabetes Care (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiovascular Function and Risk Factors
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
Keywords
SGLT2 inhibitors, EMPA-REG OUTCOME trial, cardioprotection, type 2 diabetes, hyperketonemia, beta-hydroxybutyrate, mitochondrial oxygen consumption, hemoconcentration, heart failure, cardiovascular mortality, diabetic heart disease
MeSH terms
Sodium-Glucose Transporter 2 Inhibitors, Benzhydryl Compounds, Blood Glucose, Blood Pressure, Cardiovascular Diseases, Clinical Trials as Topic, Diabetes Mellitus, Type 2, Diabetic Angiopathies, Glucosides, Heart, Humans, Hypoglycemic Agents, Models, Biological, Research Design, Treatment Outcome, 3-Hydroxybutyric Acid, Sodium-Glucose Transporter 2

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.